1 Min Read
Sept 12 (Reuters) - PCI BIOTECH HOLDING ASA
* FIRST IMMUNE RESPONSE RESULTS FROM FIMAVACC PHASE I STUDY INDICATE ENHANCED OVERALL T-CELL RESPONSES AT TOLERABLE DOSE LEVELS. Source text for Eikon: Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.